Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. bronchomycn

Bronchomycn

First in class epithelial Barrier-enhancing medicine for respiratory diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Bronchomycn project word cloud

Explore the words cloud of the Bronchomycn project. It provides you a very rough idea of what is the project "Bronchomycn" about.

give    decreasing    mill    suffered    807    clinical    belong    23    2022    2021    medical    near    market    24    speed    roi    64    decided    forecast    ebf    preclinical    regulatory    plan    2018    acts    epiendo    usa    consequence    protection    2004    caused    2    stem    morbidity    lacks    investment    epithelial    49    burden    disease    world    permeability    27    additional    bronchomycn    considering    29    prepare    antibiotic    start    structurally    respectively    commercialization    efficient    save    economic    barrier    class    2026    complications    continue    200    agents    drugs    therapeutics    ready    treatment    copd    48    obstructive    invested    people    accounted    university    commercializing    turnover    sales    health    respiratory    deaths    2024    compounds    valued    toxins    vivo    hospital    drug    azithromycin    membrane    stages    chronic    pulmonary    cell    points    million    infectious    billion    ipr    organization    2014    14    epithelium    2015    12    airway    rodents    barriolides    disorder    28   

Project "Bronchomycn" data sheet

The following table provides information about the project.

Coordinator		 EPI-ENDO PHARMACEUTICALS EHF 

Organization address
address: 28 BORGARTUNI
city: REYKJAVIK
postcode: 105
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Iceland [IS]
 Project website http://www.epiendo.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EPI-ENDO PHARMACEUTICALS EHF IS (REYKJAVIK) coordinator 50˙000.00

Map

 Project objective

Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there are no efficient drugs, being a leading cause of chronic morbidity.

According to the World Health Organization 64 million people suffered COPD in 2004. The EU-28 and USA accounted for 23 and 12.7 million people respectively, which caused near 200,000 deaths. As a consequence of the medical complications of COPD the economic burden has been estimated as € 48.4 and € 29.3 billion in EU-28 and USA respectively

EpiEndo, aims at commercializing a new drug which will be able to save € 27 billion to EU-28 and USA.

Bronchomycn belong to Barriolides, a new class of compounds that provide effective treatment against EBF. Bronchomycn is structurally based on the well-known azithromycin, but lacks antibiotic activity and it acts by decreasing the permeability of the pulmonary epithelium membrane to toxins and infectious agents.

We have been working since 2014 in collaboration with the Stem Cell Research Unit and the University Hospital and now our product is in the early in-vivo stages, for what we have invested € 0.5 Mill. In order to get Bronchomycn to the market, we will start the Clinical studies in 2018 and we expect that current knowledge about side effects of azithromycin speed up the process so that the product will be ready for commercialization in 2021.

During Phase 1 we will prepare the preclinical studies in rodents and clinical studies and defining end-points and regulatory requirements, prepare IPR protection plan, etc.

The market for Bronchomycn is the respiratory therapeutics market which was valued at € 24.8 billion in 2015. We plan to start our sales in Europe in 2022 and USA in 2024, so that by 2026 our turnover will reach €807 Mill.

Therefore, we have decided to continue with Bronchomycn for what we need an additional investment of € 49 Mill, that considering a 5-years forecast will give us a ROI of 14.2

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRONCHOMYCN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRONCHOMYCN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

SHIGETECVAX (2019)

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Read More